Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 150 of 178 entries
View as:

A Study to Evaluate the Effect of Single-Dose Intravenous Rifampin as a Prototypic Inhibitor of Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 on the Single-Dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT04121078 Org: User:
Start: 10/15/19 End: 11/16/19 Due: 11/16/20

Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT01351350 Org: User:
Start: 02/28/11 End: 09/15/17 Due: 09/15/18

A Study to Evaluate the Effect of the Potent CYP3A4 Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-906 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT03161405 Org: User:
Start: 06/05/17 End: 07/10/17 Due: 07/10/18

Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens

Phase: N/A Priority: Normal
NCT ID: NCT00610792 Org: User:
Start: 07/31/06 End: - Due: -

Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01492088 Org: User:
Start: 04/16/12 End: 04/12/18 Due: 04/12/19

Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT00948467 Org: User:
Start: 12/31/09 End: 06/30/13 Due: 06/30/14

Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia

Phase: N/A Priority: Normal
NCT ID: NCT01118689 Org: User:
Start: 11/30/10 End: 07/31/13 Due: 07/31/14

Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT04051827 Org: User:
Start: 12/23/19 End: 12/07/21 Due: 12/07/22

MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine

Phase: N/A Priority: Normal
NCT ID: NCT01397825 Org: User:
Start: 08/09/11 End: 10/05/16 Due: 10/05/17

Study of Orally Administered TAK-960 in Patients With Advanced Nonhematologic Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT01179399 Org: User:
Start: 09/30/10 End: 01/31/13 Due: 01/31/14

Phase 2 Study of the Safety and Efficacy of LDP-02 in Mildly to Moderately Active Crohn's Patients

Phase: N/A Priority: Normal
NCT ID: NCT00655135 Org: User:
Start: 02/29/00 End: - Due: -

Safety Study of TAK-700 in Subjects With Prostate Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT00569153 Org: User:
Start: 04/30/08 End: 02/28/13 Due: 02/28/14

VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00111319 Org: User:
Start: 12/31/04 End: - Due: -

Dose Escalation Study of MLN4924 in Adults With Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01011530 Org: User:
Start: 12/31/09 End: 01/31/13 Due: 01/31/14

A Study of Pevonedistat in Adult East Asian Participants

Phase: N/A Priority: Normal
NCT ID: NCT02782468 Org: User:
Start: 05/16/16 End: 01/25/22 Due: 01/25/23

A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT00830869 Org: User:
Start: 03/02/09 End: 04/20/12 Due: 04/20/13

A Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADE

Phase: N/A Priority: Normal
NCT ID: NCT00063791 Org: User:
Start: - End: - Due: -

A Study to Evaluate Drug-Drug Interaction of TAK-788 With Itraconazole and Rifampin in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT03928327 Org: User:
Start: 05/02/19 End: 08/16/19 Due: 08/16/20

A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic Function

Phase: N/A Priority: Normal
NCT ID: NCT04056468 Org: User:
Start: 10/09/20 End: 02/26/22 Due: 02/26/23

Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00807495 Org: User:
Start: 02/10/09 End: 02/13/13 Due: 02/13/14

Safety Study of TAK-593 Given Orally in Subjects With Nonhematologic Advanced Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00773929 Org: User:
Start: 01/31/09 End: 04/30/10 Due: 04/30/11

Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT01045421 Org: User:
Start: 02/28/10 End: 04/30/14 Due: 04/30/15

Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Relapsed Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00080405 Org: User:
Start: 03/31/04 End: - Due: -

Study of MLN4924 in Adult Patients With Nonhematologic Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT00677170 Org: User:
Start: 04/30/08 End: 12/31/12 Due: 12/31/13

A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00722566 Org: User:
Start: 07/31/08 End: 09/30/10 Due: 09/30/11